Impact of Adding Integrated Neuromuscular Inhibition Technique to Mulligan Therapy in Symptomatic Forward Head Posture

NCT07086872 | Not Yet Recruiting

• 1 other identifier: P.T.REC/012/005806
• Study Type: interventional
• Target: 120
• Locations: 0 countries
• Sites: N/A

Brief Summary

this study will be conducted to investigate the impact of adding integrated neuromuscular inhibition technique to mulligan therapy in symptomatic forward head posture.

Conditions

Forward Head Posture

Keywords

Integrated Neuromuscular Inhibition Technique; Mulligan Therapy; Forward Head Posture

Outcome Measures

Primary Outcomes (1)

• pain intensity

  visual analogue scale will be used to asses pain intensity which patient will be instructed to put point on line from no pain to tolerable pain. The scale consists of a line, usually 100 mm long, ranging from no pain or discomfort (zero) , to the worst pain that could possibly feel

  up to six weeks

Secondary Outcomes (4)

• neck disability

  up to 6 weeks

• pressure pain threshold

  up to six weeks

• cervical range of motion

  up to six weeks

• craniovertebral angle

  up to six weeks

Study Arms (4)

Integrated Neuromuscular Inhibition Technique and mulligan therapy

EXPERIMENTAL

thirty patients will receive Integrated Neuromuscular Inhibition Technique and mulligan therapy three times a weeks for six weeks+postural correction exercises

Other: Integrated Neuromuscular Inhibition Technique and mulligan therapy; Other: postural correction exercises

Integrated Neuromuscular Inhibition Technique

EXPERIMENTAL

thirty patients will receive Integrated Neuromuscular Inhibition Technique+postural correction exercises three times a weeks for six weeks

Other: Integrated Neuromuscular Inhibition Technique; Other: postural correction exercises

mulligan therapy

EXPERIMENTAL

thirty patients will receive mulligan Technique+postural correction exercises three times a weeks for six weeks

Other: mulligan therapy; Other: postural correction exercises

postural correction exercises

ACTIVE COMPARATOR

thirty patients will receive postural correction exercises three times a weeks for six weeks

Other: postural correction exercises

Interventions

Integrated Neuromuscular Inhibition Technique and mulligan therapy OTHER

patients will receive Integrated Neuromuscular Inhibition Technique in the form of intermittent ischemic compression, strain counter strain and muscle energy technique and mulligan therapy for limited cervical range of motion

Integrated Neuromuscular Inhibition Technique and mulligan therapy

Integrated Neuromuscular Inhibition Technique OTHER

patients will receive Integrated Neuromuscular Inhibition Technique in the form of intermittent ischemic compression, strain counter strain and muscle energy technique

Integrated Neuromuscular Inhibition Technique

mulligan therapy OTHER

patients will receive mulligan therapy for limited cervical range of motion

mulligan therapy

postural correction exercises OTHER

the patients will receive two strengthening exercises (deep cervical flexors and scapular retractors) and two stretching: cervical extensors (sub-occipital muscles) and pectoral muscles). The program was based on a program by Harman and Kendall

Integrated Neuromuscular Inhibition Technique; Integrated Neuromuscular Inhibition Technique and mulligan therapy; mulligan therapy; postural correction exercises

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• CVA equal or less than 50
• Had cervical pain for more than three months and had visited an orthopedist clinic

You may not qualify if:

• cervical spine spondylosis
• fractures or cervical spinal surgery
• Cervical or shoulder neurological movement disorder.
• Temporo-mandibular surgery, (5) Pathologic trauma

Sponsors & Collaborators

• Cairo University: lead

Central Study Contacts

alshaymaa abd elazeim, phd

CONTACT

01033771553; alshaymaa.shaaban@pt.cu.edu.eg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Masking Details: opaque sealed envelope
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: principle investigator : alshaymaa shaaban abd el azeim

Model Details: integrated neuromuscular inhibition and mulligan

Study Record Dates

• First Submitted: July 18, 2025
• First Posted: July 25, 2025
• Study Start: July 30, 2025
• Primary Completion: February 20, 2026
• Study Completion: February 20, 2026
• Last Updated: July 25, 2025

Record last verified: 2025-07